RT Journal Article
SR Electronic
T1 Vaccine Preventable Disease Seroprevalence In a Nationwide Assessment of Timor-Leste (VASINA-TL) - study protocol for a population-representative cross-sectional serosurvey
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.12.23.22283897
DO 10.1101/2022.12.23.22283897
A1 Paul Arkell
A1 Sarah L Sheridan
A1 Nelson Martins
A1 Maria Y Tanesi
A1 Nelia Gomes
A1 Salvador Amaral
A1 Tessa Oakley
A1 Vanessa Solano
A1 Michael David
A1 Anthony DK Draper
A1 Nevio Sarmento
A1 Endang da Silva
A1 Lucsendar Alves
A1 Carlito Freitas
A1 Filipe de Neri Machado
A1 Celia A Gusmão
A1 Ismael da Costa Barreto
A1 Nicholas SS Fancourt
A1 Kristine Macartney
A1 Jennifer Yan
A1 Joshua R Francis
YR 2022
UL http://medrxiv.org/content/early/2022/12/24/2022.12.23.22283897.abstract
AB Introduction Historic disruption in health infrastructure combined with data from a recent vaccine coverage survey suggests there are likely significant immunity gaps to vaccine preventable diseases and high risk of outbreaks in Timor-Leste. Community-based serological surveillance is an important tool to augment understanding of population-level immunity achieved through vaccine coverage and/or derived from prior infection.Methods and analysis This national population-representative serosurvey will take a three-stage cluster sample and aims to include 5600 individuals above one year of age. Serum samples will be collected by phlebotomy and analysed for measles immunoglobulin G (IgG), rubella IgG, severe acute respiratory syndrome coronavirus-2 anti-spike protein IgG, hepatitis B surface antibody and hepatitis B core antigen using commercially available chemiluminescent immunoassays or enzyme-linked immunosorbent assays. In addition to crude prevalence estimates and to account for differences in Timor-Leste’s age structure, we will calculate stratified age-standardised prevalence estimates, using Asia in 2013 as the standard population. Additionally, this survey will derive a national asset of serum and dried blood spot samples which can be used for further investigation of infectious disease sero-epidemiology and/or validation of existing and novel serological assays for infectious diseases.Ethics and dissemination Ethical approval has been obtained from the Research Ethics and Technical Committee of the Instituto Nacional da Saúde,Timor-Leste and the Human Research Ethics Committee of the Northern Territory Department of Health and Menzies School of Health Research, Australia. Co-designing this study with Timor-Leste Ministry-of-Health and other relevant partner organisations will allow immediate translation of findings into public health policy (which may include changes to routine immunisation service delivery and/or plans for supplementary immunisation activities).STRENGTHS AND LIMITATIONS OF THIS STUDY This project is one of very few large-scale, community-based, population-representative serosurveys to be conducted in low-middle income countries.It will provide accurate seroprevalence estimates for multiple vaccine-preventable diseases, which will immediately inform public health policy and support an ongoing programme of vaccine research in Timor-Leste and the surrounding region.A national asset of bio-banked serum samples will be derived, which can be used in cross-sectional and prospective studies of infectious disease epidemiology, including those which evaluate disease control interventions.Diverse, remote communities across Timor-Leste will be visited, with primary sample analysis occurring at the National Health Laboratory in Timor-Leste. Therefore, fieldwork and laboratory-related logistical challenges will need to be overcome.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the Department for Foreign Affairs and Trade, Australian Government (Complex Grant Agreement Number 75889).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Research Ethics and Technical Committee of the Instituto Nacional da Saude,Timor-Leste (Reference: 875 MS-INS/DGE/IX/2021) Human Research Ethics Committee of the Northern Territory Department of Health and Menzies School of Health Research, Australia (Reference: 2021-4064).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesStudy protocol paper, therefore no data currently